News

Cookie Notice

This Cookie Policy was last updated on February 24, 2024. We are Sling Therapeutics, Inc. (“Company,” “we,” “us,” “our “), a company registered in Michigan, United States at 455 E. Eisenhower Pkwy, Suite 300 PMB1048, Ann Arbor, MI 48108. We operate the website https://www.slingtx.com (the “Site“), which is intended only for users who reside…

Read MoreCookie Notice

Sling Therapeutics Announces Publication Demonstrating Attenuation of Pathologic Bone Marrow Activity with Linsitinib in a Mouse Model of Thyroid Eye Disease

– Linsitinib inhibited the formation of CD4+ T-cells in bone marrow, which are upregulated and clinically relevant in Thyroid Eye Disease (TED) – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for treatment of active, moderate to severe…

Read MoreSling Therapeutics Announces Publication Demonstrating Attenuation of Pathologic Bone Marrow Activity with Linsitinib in a Mouse Model of Thyroid Eye Disease

Sling Therapeutics Presents Preclinical Data Demonstrating Treatment with Linsitinib Limits Progression of Thyroid Eye Disease at 45th Annual Meeting of European Thyroid Association

– Results highlighted in oral presentation show linsitinib significantly limited disease severity in early- and late-stage TED mouse models and prevented development of autoimmune response – – Company currently evaluating linsitinib in ongoing global Phase 2b LIDS clinical trial in…

Read MoreSling Therapeutics Presents Preclinical Data Demonstrating Treatment with Linsitinib Limits Progression of Thyroid Eye Disease at 45th Annual Meeting of European Thyroid Association

Sling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023

– Treatment with linsitinib in a clinically relevant mouse model demonstrated a significant reduction in autoimmune response and classical Thyroid Eye Disease (TED) symptoms, independent of TED severity – – Ongoing global Phase 2b LIDS clinical trial evaluating linsitinib for…

Read MoreSling Therapeutics Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease Progression in a Mouse Model at ENDO 2023

Sling Therapeutics Presents Preclinical Data Demonstrating Linsitinib Decreases Immune Response in Mouse Model of Thyroid Eye Disease at IMMUNOLOGY2023™

– Data demonstrate significant improvements in clinically relevant endpoints including reduced inflammation of fat and muscle behind the eye – – Company evaluating linsitinib in global Phase 2b LIDS clinical trial for treatment of active, moderate to severe thyroid eye…

Read MoreSling Therapeutics Presents Preclinical Data Demonstrating Linsitinib Decreases Immune Response in Mouse Model of Thyroid Eye Disease at IMMUNOLOGY2023™